UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

A light at the end of the dark tunnel of depression? Doctors commonly prescribe antidepressants to treat patients suffering ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to present promising 12-month data from its Phase 2 study of CYB003, aimed at ...

Cybin Inc. CYBN has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .